BYM338 vs Methoxy PEG-Epoetin Beta
Head-to-head comparison of BYM338 (Bimagrumab (BYM338)) and Methoxy PEG-Epoetin Beta (Methoxy polyethylene glycol-epoetin beta (CERA)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | BYM338 | Methoxy PEG-Epoetin Beta |
|---|---|---|
| Category | Muscle & Performance | Muscle & Performance |
| Full Name | Bimagrumab (BYM338) | Methoxy polyethylene glycol-epoetin beta (CERA) |
| Molecular Weight | ~148 kDa | ≈60,000 Da |
| Half-Life | ~2-3 weeks | ~130 h |
| Amino Acids | N/A | 165 |
| Typical Dose | 10-30 mg/kg IV in trials | 0.6 mcg/kg SC every 2 weeks or 1.2 mcg/kg SC monthly |
| Route | Intravenous | Subcutaneous/IV |
| Purity | ≥98% | ≥98% |
| Studies Count | 140 | 95 |
| Research Status | Clinical | Clinical |
BYM338 Benefits
- ✓increased lean mass
- ✓functional strength support
- ✓reduced muscle wasting
- ✓metabolic body-composition shift
Methoxy PEG-Epoetin Beta Benefits
- ✓long-acting erythropoiesis
- ✓stable hemoglobin
- ✓fewer injections
- ✓improved oxygen delivery
BYM338 Dosing
IV infusion|10-30 mg/kg per study cycle|repeat every 4-12 weeks
Methoxy PEG-Epoetin Beta Dosing
0.6 mcg/kg SC every 2 weeks|1.2 mcg/kg SC monthly|Adjust based on hemoglobin
BYM338 Side Effects
- ⚠muscle cramps
- ⚠diarrhea/nausea
- ⚠infusion reactions
Methoxy PEG-Epoetin Beta Side Effects
- ⚠hypertension
- ⚠thromboembolism
- ⚠headache
Research Overview
BYM338
Clinical trials showed meaningful increases in lean mass, with mixed functional outcomes depending on population and endpoint. The antibody remains one of the best-documented receptor-blocking approaches to muscle anabolism in humans.
Methoxy PEG-Epoetin Beta
Clinical trials show predictable hemoglobin correction with a long dosing interval and sustained red-cell stimulation. Any VO2 max effect would be secondary to higher hemoglobin, not a direct ergogenic mechanism.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.